Due to the presence of a strong driver mutation (BCR‐ABL1) and the lack of a potent tumor suppressor (Arf), these cells are capable of establishing leukemia in mice without myeloablation, which leaves the immune system unperturbed (Boulos et al., 2011; Manlove et al., 2015; Rabe et al., 2019; Williams et al., 2006, 2007). The gene discussed is CDKN2A; the disease is leukemia.